Erik Berg is the founder of AM Pharma. AM Pharma has raised $176M in total funding. Latest round: Series C. Backed by LSP, Andera Partners, Forbion.
Erik van den Berg is the CEO of AM-Pharma, a clinical stage biopharmaceutical company developing a treatment for acute kidney injury (AKI). Under his leadership, the company secured significant funding rounds to advance its recombinant human Alkaline Phosphatase (recAP) therapeutic through pivotal Phase III trials.
Full founder directory · Investor directory · Company funding database · Fundraising library